Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	10.73K -63.6%
Revenue (ttm)	386.00K -95.6%
Net Income	-97.82M
EPS	-2.66
Shares Out	26.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	904
Open	0.0004
Previous Close	0.0004
Day's Range	0.0004 - 0.0005
52-Week Range	0.000001 - 0.0200
Beta	1.73
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYRS

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error